Immuron Confirmed as Buy Opportunity Following Strong First-Half Revenue Data

New York, Thursday, 22 January 2026.
Emerging Growth Research has maintained a ‘Buy-Extended’ rating for Immuron Limited, reaffirming a $3.50 price target as of January 22, 2026. This positive outlook is underpinned by tangible financial performance, specifically a 5% increase in global revenue to AUD$4.2 million for the half-year ending December 31, 2025. Crucially, the analysis highlights a 17% revenue surge in the United States and a 13% increase in Australia, driven by robust demand for the company’s flagship travel health supplement, Travelan®. This commercial momentum, further bolstered by the December 2025 launch of the digestive health product ProIBS®, supports the valuation despite standard biopharmaceutical capital risks.